Talk:Ensitrelvir

USA

https://asia.nikkei.com/Spotlight/Coronavirus/Shionogi-in-talks-with-U.S.-to-supply-COVID-oral-drug 2600:1700:8660:E180:35:9F96:F2C6:2D0F (talk) 05:56, 25 April 2022 (UTC)

Approved

https://www.shionogi.com/global/en/news/2022/11/e20221122.html

https://www.bloomberg.com/news/articles/2022-11-22/shionogi-s-covid-pill-xocova-wins-japanese-panel-backing 97.35.0.38 (talk) 15:10, 26 November 2022 (UTC)

china

https://asia.nikkei.com/Business/Pharmaceuticals/Drugmaker-Shionogi-inks-deal-to-market-COVID-pill-in-China 172.87.166.242 (talk) 16:48, 30 December 2022 (UTC)

https://www.shionogi.com/global/en/news.html

Jun.26, 2023 Seven manufacturers sign sublicence agreements with the Medicines Patent Pool to produce generic versions of #Shionogi's COVID-19 oral antiviral ensitrelvir to increase access in low- and middle-income countries.

https://www.shionogi.com/global/en/news/2023/6/20230626-2.html

2023/06/26

Under the terms of the licence agreement, the seven selected generic manufacturers will be able to manufacture and supply ensitrelvir in 117 low- and middle-income countries (LMICs), pending regulatory authorisation or approval in those countries.

At least these countries are mentioned: Ukraine, China, South Africa.

Apr.11, 2023 Shionogi filed for Emergency Use Authorization of Ensitrelvir Fumaric Acid in Taiwan, for the Treatment of COVID-19

Apr.04, 2023 Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid, an Investigational Oral Antiviral for COVID-19

Jan.04, 2023 New Drug Application of Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19 Accepted for Review in South Korea

91.159.186.9 (talk) 17:14, 29 July 2023 (UTC)

south korea

https://asia.nikkei.com/Spotlight/Coronavirus/Japan-s-Shionogi-seeks-approval-for-COVID-pill-in-South-Korea 2600:8804:6600:45:78FF:CBD5:85A4:C357 (talk) 01:30, 5 January 2023 (UTC)

Ensitrelvir (Xocova) and Nirmatrelvir (Paxlovid) are both sars2 main protease inhibitors

Ensitrelvir (Xocova) and Nirmatrelvir (Paxlovid) are both sars2 main protease inhibitors

It should be mentioned that they have the same mechanism of action.

It is good Paxlovid has a competitor.

https://en.wikipedia.org/wiki/Nirmatrelvir/ritonavir

Other covid-19 drugs have different mechanisms, for example Molnupiravir.

91.159.186.9 (talk) 17:05, 29 July 2023 (UTC)

The structure is also quite refreshingly new. It looks nothing like a peptide -- well, maybe a tiny bit, but much less compared to Paxlovid. And the way it binds (PDB: 8DZ1​) is cool. Might be a good idea to seek out some articles about the design process (doi:10.1021/acsomega.2c03881 looks good). (Holy moly, the article says it also inhibits ExoN and RdRP.) Artoria2e5 🌉 14:21, 2 October 2023 (UTC)